• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

纳武利尤单抗治疗晚期转移性非小细胞肺癌的日本患者：疗效和安全性临床试验证据的综述。

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

机构信息

Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

出版信息

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.

DOI:10.1177/1753466618801167
PMID:30249170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6156204/
Abstract

Programmed cell death (PD)-1 immune checkpoint inhibitors have emerged as promising options for the treatment of multiple cancer types. Nivolumab is a fully human immunoglobulin G4 monoclonal antibody, which inhibits the PD-1 receptor and has been approved in the United States, Europe, and Asia for the treatment of advanced NSCLC. This review focuses on nivolumab's efficacy and safety in the treatment of NSCLC patients in Japan.

摘要

程序性细胞死亡（PD）-1免疫检查点抑制剂已成为多种癌症治疗的有前途的选择。尼伏鲁单抗是一种完全人源 IgG4 单克隆抗体，可抑制 PD-1 受体，已在美国、欧洲和亚洲获批用于治疗晚期 NSCLC。本综述重点介绍尼伏鲁单抗在日本治疗 NSCLC 患者中的疗效和安全性。

相似文献

1
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.纳武利尤单抗治疗晚期转移性非小细胞肺癌的日本患者：疗效和安全性临床试验证据的综述。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.
2
Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.两项 nivolumab 治疗既往接受治疗的晚期非小细胞肺癌日本患者的 II 期研究的 3 年随访结果：ONO-4538-05 和 ONO-4538-06 研究的汇总分析。
Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.
3
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.分析接受抗 PD-1 治疗的晚期非小细胞肺癌患者的预先存在的抗体。
JAMA Oncol. 2019 Mar 1;5(3):376-383. doi: 10.1001/jamaoncol.2018.5860.
4
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer.新辅助 PD-1 抑制治疗非小细胞肺癌的计算模型。
AAPS J. 2019 Jun 24;21(5):79. doi: 10.1208/s12248-019-0350-x.
5
Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.纳武单抗诱导的转移性非小细胞肺癌患者免疫性血小板减少症
Oncol Res Treat. 2017;40(10):621-622. doi: 10.1159/000477968. Epub 2017 Sep 19.
6
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.ALT-803，一种白细胞介素-15 超级激动剂，联合纳武利尤单抗用于转移性非小细胞肺癌患者：一项非随机、开放标签、Ib 期试验。
Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.
7
Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.在鳞状细胞非小细胞肺癌中使用抗PD-L1药物克服对PD-1抑制剂的原发性耐药：病例报告
Clin Lung Cancer. 2020 Mar;21(2):e45-e48. doi: 10.1016/j.cllc.2019.11.011. Epub 2019 Nov 20.
8
Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.促进抗 PD-1 治疗的疗效：纳武利尤单抗联合放疗治疗晚期非小细胞肺癌 - FORCE 试验研究方案。
BMC Cancer. 2019 Nov 8;19(1):1074. doi: 10.1186/s12885-019-6205-0.
9
Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.真实世界实践中抗 PD-1 治疗的非小细胞肺癌患者的特征和治疗结局的综合分析。
J Cancer Res Clin Oncol. 2019 Jun;145(6):1613-1623. doi: 10.1007/s00432-019-02899-y. Epub 2019 Mar 25.
10
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.纳武利尤单抗治疗后进展的晚期非小细胞肺癌患者接受帕博利珠单抗治疗：12 例病例的报告。
Cancer Chemother Pharmacol. 2018 Jun;81(6):1105-1109. doi: 10.1007/s00280-018-3585-9. Epub 2018 Apr 19.

引用本文的文献

1
A novel pyroptosis-regulated gene signature for predicting prognosis and immunotherapy response in hepatocellular carcinoma.一种用于预测肝细胞癌预后和免疫治疗反应的新型焦亡调节基因特征。
Front Mol Biosci. 2022 Sep 5;9:890215. doi: 10.3389/fmolb.2022.890215. eCollection 2022.
2
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis.一线度伐利尤单抗联合铂类-依托泊苷治疗广泛期小细胞肺癌：CASPIAN日本亚组分析
Int J Clin Oncol. 2021 Jun;26(6):1073-1082. doi: 10.1007/s10147-021-01899-8. Epub 2021 Apr 7.
3
Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.当前对肝癌免疫抑制性肿瘤微环境的认识：挑战与机遇。
Mol Cancer. 2019 Aug 29;18(1):130. doi: 10.1186/s12943-019-1047-6.

本文引用的文献

1
Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.纳武利尤单抗用于日本晚期或复发性非鳞状非小细胞肺癌患者的多中心II期研究。
ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016.
2
Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.纳武利尤单抗在日本晚期或复发性鳞状非小细胞肺癌患者中的疗效和安全性。
Cancer Sci. 2017 May;108(5):1000-1006. doi: 10.1111/cas.13225. Epub 2017 Apr 26.
3
Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.纳武利尤单抗相关的间质性肺病分析：两项复发或晚期非小细胞肺癌患者的 II 期研究。
Lung Cancer. 2017 Feb;104:111-118. doi: 10.1016/j.lungcan.2016.12.016. Epub 2016 Dec 21.
4
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.抗程序性死亡蛋白1（PD-1）抗体纳武单抗用于恶性实体瘤患者的I期研究。
Invest New Drugs. 2017 Apr;35(2):207-216. doi: 10.1007/s10637-016-0411-2. Epub 2016 Dec 8.
5
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.纳武单抗与标准化疗药物联合应用于晚期非小细胞肺癌患者的安全性和疗效：一项四臂Ib期研究。
Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20.
6
Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer.纳武利尤单抗用于转移性鳞状非小细胞肺癌的二线治疗。
Am J Health Syst Pharm. 2015 Nov 1;72(21):1851-5. doi: 10.2146/ajhp150235.
7
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
8
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
9
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.纳武单抗（抗程序性死亡1抗体，BMS-936558，ONO-4538）用于既往治疗过的晚期非小细胞肺癌患者的总生存期和长期安全性
J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708. Epub 2015 Apr 20.
10
Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.接受纳武利尤单抗治疗的既往治疗过的晚期肾细胞癌患者的生存、持久缓解及长期安全性
J Clin Oncol. 2015 Jun 20;33(18):2013-20. doi: 10.1200/JCO.2014.58.1041. Epub 2015 Mar 30.